Work

Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy

Year: 2016

Type: article

Abstract: // Wanqi Zhu 1 , Li Jia 3 , Guanxuan Chen 2 , Hanxi Zhao 1 , Xiaorong Sun 4 , Xiangjiao Meng 1 , Xianguang Zhao 1 , Ligang Xing 1 , Jinming Yu 1, 2 , Meizhu Zheng 2 1 Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, Shandong, China 2 Shandong Key Laboratory of Radiation Oncology, Jinan, Shandong, China 3 Department of Radiation Oncology, Jinan Fourth People’s Hospital, Jinan, Shandong, China 4 Department of Radiology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, Shandong, China Correspondence to: Hanxi Zhao, email: [email protected] Ligang Xing, email: [email protected] Keywords: epigallocatechin-3-gallate, breast neoplasms, dermatitis, radiation Received: December 21, 2015 Accepted: May 04, 2016 Published: May 20, 2016 ABSTRACT There are few effective treatment options for radiation-induced dermatitis in breast cancer patients. We conducted a single-arm trial to tested the hypothesis that topical epigallocatechin-3-gallate (EGCG) is effective against radiation-induced dermatitis in breast cancer patients undergoing radiotherapy. Forty-nine patients participated in this study. The patients underwent mastectomy followed by adjuvant radiotherapy. Topical EGCG was applied daily, starting when grade I dermatitis appeared and ending two weeks after radiotherapy. The maximum dermatitis observed during the EGCG treatment was as follows: Grade 1 toxicity, 71.4% (35 patients); grade 2 toxicity, 28.6% (14 patients); there were no patients with grade 3 or 4 toxicity. The majority of the radiation-induced dermatitis was observed 1 week after the end of radiotherapy. EGCG reduced the pain in 85.7% of patients, burning-feeling in 89.8%, itching in 87.8%, pulling in 71.4%, and tenderness in 79.6%. These findings suggest topical EGCG may be an effective treatment for radiation-induced dermatitis and has acceptable toxicity.

Source: Oncotarget

DOI: 10.18632/oncotarget.9495